Kidney Function Tracking in Mexico Reaches a Large Prospective Mortality Cohort
A long-running Mexican cohort has put kidney function back at the center of mortality research in a setting where diabetes and chronic kidney disease carry heavy population-level consequences. The Mexico City Prospective Study followed adults recruited between 1998 and 2004 and tracked them through October 2022, giving investigators a rare chance to examine how estimated glomerular filtration rate relates to death across a large middle-aged and older adult population in Mexico.
The analysis focused on 126,245 participants aged 35 to 74 years at recruitment who had no prior disease aside from diabetes or chronic kidney disease. Among them, 40,996 were men and 85,249 were women. Median eGFR was 102 mL/min/1.73 m2, with an interquartile range of 91 to 110, which means most participants entered the study with kidney function in the normal or near-normal range rather than in advanced failure.
Even in a cohort with relatively preserved baseline kidney function, 12,590 participants died during a median follow-up of 20.4 years. The study was designed to test cause-specific mortality, not only all-cause death, and that distinction matters because kidney dysfunction does not act through a single pathway. Reduced filtration can track with vascular injury, metabolic derangement, fluid overload, and progressive organ damage, all of which may shift the pattern of death across cardiovascular, renal, and other causes.
Why Kidney Function Carries Broad Prognostic Weight
The biological logic behind the study is straightforward. Kidney impairment rarely remains confined to the kidneys. As filtration declines, patients accumulate toxins, lose physiologic reserve, and face worsening blood pressure control, anemia, inflammation, and vascular stiffness. In countries where diabetes is common, those processes can compound each other for years before overt kidney failure appears.
Mexico is an especially important setting for this question. Diabetes is common, and chronic kidney disease remains a major cause of morbidity and mortality. Much of the earlier evidence linking eGFR to death came from high-income populations, so the current cohort helps test whether that association extends cleanly into a different epidemiologic environment with distinct background risks, health-system constraints, and disease patterns.
The cohort’s size gives it unusual statistical reach. With more than 126,000 adults and more than 12,000 deaths, the study is large enough to examine how kidney function behaves as a graded exposure rather than as a simple yes-or-no diagnosis. In real clinical practice, risk rarely changes abruptly at the threshold used to define chronic kidney disease. It usually rises stepwise as kidney reserve erodes.
Baseline Profile Suggests a Population at Metabolic Risk
The average body mass index in the cohort was 29.1 kg/m2, with a standard deviation of 4.9 kg/m2, placing the mean participant in the overweight range. Thirteen percent had previously diagnosed diabetes, and 1% self-reported chronic kidney disease at baseline. Those numbers matter because they define the metabolic terrain in which eGFR operates: insulin resistance, obesity, and diabetes can accelerate vascular and renal injury long before clinicians document severe creatinine elevation or overt uremic symptoms.
A study of this size also captures the long tail of risk. Some participants likely entered follow-up with subtle kidney impairment that did not meet a clinical threshold for chronic kidney disease, yet still carried prognostic significance. In a population where diabetes is prevalent, modest decrements in eGFR can signal systemic microvascular disease rather than an isolated laboratory abnormality.
The cohort design is prospective, and that adds interpretive strength. Kidney function was measured before the mortality events accumulated, which reduces the chance that late-stage illness alone explains the association. Cox regression was used to relate eGFR to cause-specific mortality, with adjustment for sociodemographic and lifestyle factors, anthropometry, and diabetes.
Cause-Specific Mortality Remains the Critical Missing Detail Here
The abstract excerpt available here stops before the numerical hazard estimates and cause-specific results. No hazard ratios, no mortality subtype estimates, and no threshold effects are provided in the source material supplied for this rewrite. What is clear is that the investigators set out to map kidney function onto death from specific causes, not just overall survival, in a cohort large enough to support that analysis.
That endpoint structure is clinically meaningful. If lower eGFR maps more strongly to cardiovascular death, the implication would be intensified vascular risk management. If renal death rises in parallel, it would support earlier nephrology referral and closer surveillance for progression. If diabetes-linked mortality clusters across several cause categories, it would reinforce the idea that kidney dysfunction is acting as a marker of broader systemic injury rather than a single-organ problem.
Because the supplied abstract ends before those results are listed, the safest interpretation is procedural rather than inferential. The study establishes a powerful platform for understanding how kidney function predicts death in Mexico over two decades of observation. The missing hazard estimates are the essential next layer, because they would show whether mild impairment, moderate reduction, or more advanced loss of filtration carried the steepest penalty across specific mortality categories.
A Population-Level Lens on Chronic Kidney Disease Risk
For clinicians, the practical value of a study like this lies in its scale and setting. Middle-aged and older adults with preserved kidney function at baseline are often reassured by a single normal laboratory value, yet the trajectory of eGFR over time can still reveal substantial risk. In a country with a high diabetes burden, that trajectory may be especially important for identifying who needs tighter cardiometabolic control before irreversible decline sets in.
The study also reinforces a basic nephrology principle: kidney function is not merely a renal metric. It is a summary marker of systemic health, vascular integrity, and long-term physiologic reserve. When eGFR falls, death risk often rises because several disease pathways converge at once—cardiovascular injury, diabetic complications, progressive renal failure, and susceptibility to decompensation from otherwise manageable illness.
One line in the dataset captures the urgency of that point. Twelve thousand five hundred ninety deaths accumulated during follow-up. In a cohort this large, mortality is not an abstract statistic; it is the endpoint of decades of cumulative cardiometabolic stress, much of it potentially detectable through kidney function long before the final event.
The decisive clinical question now rests on the unreported hazard ratios and cause-specific estimates. Those numbers will determine whether kidney function should be treated mainly as a broad mortality marker in this setting or as a sharper guide to specific preventive strategies for diabetes, cardiovascular disease, and renal progression.